MBIO · Mustang Bio Inc

-

Please sign in to comment on MBIO

1 Comment

Admin

4 years, 1 month ago

Mustang Bio, Inc is currently in a long term downtrend where the price is trading 11.6% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Mustang Bio, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 99.6% to $-60K since the same quarter in the previous year.

Finally, its free cash flow grew by 3.5% to $-10M since the same quarter in the previous year.

Based on the above factors, Mustang Bio, Inc gets an overall score of 3/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US62818Q1040
Sector	Healthcare
Industry	Biotechnology

Beta	2.27
Target Price	10
Market Cap	4M
PE Ratio	None
Dividend Yield	None

ABOUT

Mustang Bio Inc

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

MBIO · Mustang Bio Inc

-

Mustang Bio Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Mustang Bio Inc using a moving average strategy